Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Duavee Approved For Hot Flashes, Osteoporosis Prevention

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA cleared the single pill combining conjugated estrogens with bazedoxifene, a novel selective estrogen receptor modulator, for two indications but issued a “complete response” letter for use in vulvar and vaginal atrophy.

You may also be interested in...



FDA Shutdown Plans For 2015: Same As 2013, But With More People

'Limited activities related to user fee funded programs' will continue if Congress does not pass a short-term funding measure by Oct. 1.

European Backing For AstraZeneca’s Olaparib Bolsters Barriers To Pfizer

Europe’s top medicines advisory panel, the CHMP, also recommended for approval Clinuvel’s Scenesse for severe intolerance to sunlight, Pfizer’s new combination menopausal symptom therapy Duavive, and Baxter’s new hemophilia B therapy Rixubis.

FDA Shutdown Hangover Hurts Biosimilars, May Benefit Some ANDAs

As normal operations – and normal budget worries – resume, the agency has some meetings to reschedule.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel